US20220233621A1 - Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue - Google Patents
Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue Download PDFInfo
- Publication number
- US20220233621A1 US20220233621A1 US17/717,203 US202217717203A US2022233621A1 US 20220233621 A1 US20220233621 A1 US 20220233621A1 US 202217717203 A US202217717203 A US 202217717203A US 2022233621 A1 US2022233621 A1 US 2022233621A1
- Authority
- US
- United States
- Prior art keywords
- fatigue
- pharmaceutical composition
- cannabis
- present
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 57
- 238000000034 method Methods 0.000 title abstract description 10
- 240000004308 marijuana Species 0.000 title 1
- 241000218236 Cannabis Species 0.000 claims abstract description 43
- 229930091371 Fructose Natural products 0.000 claims abstract description 21
- 239000005715 Fructose Substances 0.000 claims abstract description 21
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 21
- 239000002775 capsule Substances 0.000 claims description 24
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 23
- 239000007894 caplet Substances 0.000 claims description 22
- 239000007933 dermal patch Substances 0.000 claims description 22
- 229930003761 Vitamin B9 Natural products 0.000 claims description 5
- 235000019159 vitamin B9 Nutrition 0.000 claims description 5
- 239000011727 vitamin B9 Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 3
- 235000020733 paullinia cupana extract Nutrition 0.000 claims 3
- 229940045999 vitamin b 12 Drugs 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 abstract description 12
- 229930003231 vitamin Natural products 0.000 abstract description 12
- 235000013343 vitamin Nutrition 0.000 abstract description 12
- 239000011782 vitamin Substances 0.000 abstract description 12
- 239000004615 ingredient Substances 0.000 abstract description 3
- 206010016256 fatigue Diseases 0.000 description 62
- 239000000203 mixture Substances 0.000 description 29
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 20
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 229960004242 dronabinol Drugs 0.000 description 17
- 235000019152 folic acid Nutrition 0.000 description 15
- 239000011724 folic acid Substances 0.000 description 15
- 240000003444 Paullinia cupana Species 0.000 description 14
- 235000000556 Paullinia cupana Nutrition 0.000 description 14
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 13
- 244000269722 Thea sinensis Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229930003779 Vitamin B12 Natural products 0.000 description 11
- 229940014144 folate Drugs 0.000 description 11
- 235000008216 herbs Nutrition 0.000 description 11
- 235000019163 vitamin B12 Nutrition 0.000 description 11
- 239000011715 vitamin B12 Substances 0.000 description 11
- 235000006468 Thea sinensis Nutrition 0.000 description 10
- 238000011282 treatment Methods 0.000 description 8
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 7
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 7
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 7
- 229950011318 cannabidiol Drugs 0.000 description 7
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 6
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229930003827 cannabinoid Natural products 0.000 description 6
- 239000003557 cannabinoid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000019914 Mental Fatigue Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VITZNDKHSIWPSR-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-4-carboxylic acid Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=C(C(O)=O)C(CCCCC)=CC(O)=C3[C@@H]21 VITZNDKHSIWPSR-HZPDHXFCSA-N 0.000 description 4
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 4
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 4
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010016880 Folate deficiency Diseases 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- ZPNWJGPRXXTUNI-UHFFFAOYSA-N 1-(1h-indol-2-yl)-2-phenylethanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)CC1=CC=CC=C1 ZPNWJGPRXXTUNI-UHFFFAOYSA-N 0.000 description 2
- SZQZAUQREUIIJH-UHFFFAOYSA-N 1h-indol-2-yl(naphthalen-1-yl)methanone Chemical compound C1=CC=C2C(C(C=3NC4=CC=CC=C4C=3)=O)=CC=CC2=C1 SZQZAUQREUIIJH-UHFFFAOYSA-N 0.000 description 2
- RLGAYEJPGHIHIB-UHFFFAOYSA-N 1h-indol-2-yl(phenyl)methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 RLGAYEJPGHIHIB-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 240000006890 Erythroxylum coca Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000533293 Sesbania emerus Species 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- -1 but not limited to Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 235000008957 cocaer Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 241000218235 Cannabaceae Species 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 description 1
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 description 1
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 description 1
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- the present invention relates to pharmaceutical compositions comprising Cannabis and methods for improving energy and/or alleviating fatigue.
- Fatigue can be due to physical fatigue associated with excess activity or working out and mental fatigue associated with sleep deprivation, depression, boredom, jet lagged and stress.
- Mental fatigue does give the subjective feeling of physical fatigue. Fatigue also is commonly caused by many medical conditions such as thyroid disease, heart disease, chronic obstructive pulmonary disease (COPD), anemia, and infectious diseases such as the flu.
- COPD chronic obstructive pulmonary disease
- the number of treatment options is limited. Usually if it is a treatable medical condition such as anemia or a limited disease state such as the flu, patients have the underlying pathology treated with time, rehydration and rest. Similarly, in situations where it is physical fatigue patients can their symptoms improved by rest, rehydration and eating a balanced diet. However, many patients who suffer from mental fatigue have a more challenging time getting relief from the symptoms of fatigue.
- Cannabis is a drug that can cause or contribute to fatigue at higher doses and when formulated with lower levels of THC (tetrahydrocannabinol) or less than about 10 mg of THC.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, comprise alone or in combination, therapeutically effective amounts of Cannabis and/or herbs for use as a medicinal product prescribed by a physician, a health care practitioner or an over-the-counter product available at pharmacies, marijuana dispensaries and/or mass food stores.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Camellia sinesis.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Paullinia cupana (also known as guarana or Brazilian coca).
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Folate.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Vitamin B12.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Fructose.
- a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects.
- the pharmaceutical composition may preferably, but need not necessarily, comprise therapeutically effective amounts of Cannabis in any of the following form cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC), a naphthoylindole, a phenylacetylindole, a benzoylindole, a cyclohexylphenole, delta-9 tetrahydrocannabinol (THC or dronabinol), delta-8 tetrahydrocannabinol (
- a pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient.
- the pharmaceutical composition may preferably, but need not necessarily, comprise a pharmaceutically acceptable excipient selected from any of the group consisting of: hydroxypropylcellulose, starch, silicon dioxide, gelatin, magnesium stearate, or microcrystalline cellulose.
- a pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient.
- the pharmaceutical composition may preferably, but need not necessarily, comprise the form of a tablet, caplet, capsule, dermal patch, oil drops, powder or a suspension.
- the present invention can be implemented in numerous ways, including as a use of the pharmaceutical composition or a method for increasing energy levels and/or alleviating fatigue in a patient.
- these implementations, or any other form that the invention may take, may be referred to as uses or methods.
- the order of the steps of the disclosed methods may be altered within the scope of the invention.
- energy or “energetic” to generally mean to possess, exert, or display the ability to do physical work. It is the ability and strength to do active physical things and a feeling of physical power and life.
- Fatigue to generally mean a feeling of tiredness which is distinct from weakness and has a gradual onset. Fatigue can have physical or mental causes. Physical fatigue is the transient inability of a muscle to maintain optimal physical performance. Mental fatigue is a transient decrease in maximal cognitive performance resulting from prolonged periods of cognitive activity and can manifest as somnolence, lethargy or directed attention fatigue.
- treatment to generally refer to an approach for obtaining beneficial or desired results.
- beneficial or desired results can include, but are not limited to, prevention or prophylaxis, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- a person skilled in the relevant art may generally understand the term “therapeutically effective amount” to be an amount sufficient to effect treatment when administered to a subject in need of treatment.
- a therapeutically effective amount can include, but is not limited to, an amount for increasing energy levels and/or alleviating fatigue in a patient.
- compositions of the present invention can be formulated into pharmaceutical compositions for administration in a manner customary for administration of such materials using standard pharmaceutical formulation chemistries and methodologies, all of which are readily available to a person skilled in the relevant art.
- pharmaceutical compositions may include one or more excipients, carriers, stabilizers or other pharmaceutically inactive compounds, such as, but not limited to, wetting or emulsifying agents, pH buffering substances, hydroxypropylcellulose, starch, silicon dioxide, gelatin, magnesium stearate, microcrystalline cellulose and the like.
- Pharmaceutically acceptable salts can also be included therein.
- compositions can be prepared as oral or transdermal preparations.
- the therapeutically effective doses may vary according to body weight and the timing and duration of administration will be determined by specific clinical research protocols.
- dose refers to the measured quantity of an agent, preferably a therapeutic agent, to be taken at one time to have a desired therapeutic effect(s).
- dose as used herein means a specified quantity of a pharmaceutical or therapeutic agent provided in one or more administration.
- any known dosage form may be employed with the present invention. These may include, solid dosage forms, liquid dosage forms, gel dosage forms, etc.
- effective dose or “effective dosage” is defined as an amount sufficient to achieve or at least partially achieve the desired effect.
- therapeutically effective dose is defined as an amount sufficient to cure or at least partially arrest the disease and/or one or more associated symptoms in a patient already suffering from the disease.
- administering means providing a therapeutically active agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering.
- a “pharmaceutical agent” or “therapeutic agent” as used herein means a substance that provides a therapeutic effect when administered to a subject.
- “Pharmaceutical composition” means a mixture of substances suitable for administering to an individual that includes one or more pharmaceutical or therapeutically effective agents.
- active pharmaceutical ingredient shall be understood to refer to a substance in a pharmaceutical composition that provides a desired effect.
- the treatment of low energy levels and/or fatigue in accordance with the present invention and as hereinafter defined for the purposes of this invention is directed to the improvement of energy levels and/or alleviating fatigue—including or in particularly mental fatigue—as defined herein.
- an agent or agents which can treat low energy levels and/or fatigue is recommended. Since no pharmaceutical composition containing Cannabis is presently capable of treating low energy levels and/or fatigue, a pharmaceutical composition such as is described in the present invention is recommended.
- Preferred embodiments of the present invention treat low energy levels and/or fatigue.
- the pharmaceutical compositions of the present invention may be provided with different active ingredients, different strengths and/or different formulations.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Cannabis .
- Cannabis is one of a class of diverse chemical compounds that acts on cannabinoid receptors (e.g., cannabinoid receptor type 1, cannabinoid receptor type 2) in cells that alter neurotransmitter release in the brain.
- the pharmaceutical composition may comprise Cannabis -derived cannabinoids selected from the group consisting of: cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC), a naphthoylindole, a phenylacetylindole, a benzoylindole, a cyclohexylphenole, delta-9 tetrahydrocannabinol (THC or dronabinol), delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabinol acid (THCA),
- compositions comprising a therapeutically effective amount of Cannabis may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- Cannabis may be present in the composition in a particulate form with at least 50% by wt of the particles ranging in size from about 50 micron to about 2000 micron and wherein the particles comprise a cannabinoid, cannabinoid derivative, a terpene or a mixture thereof in a range of 1 to 30 mg of cannabinoid (CBD or THC) and most preferably from about 2.5 mg to about 10 mg per dose.
- CBD cannabinoid
- the pharmaceutical composition of the present invention may also comprise a therapeutically effective amount of one or more herbs, including but not limited to: Camellia sinensis; Paullinia cupana ; and combinations thereof.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Camellia sinensis (green tea).
- Camellia sinensis is a species of evergreen shrub or small tree whose leaves and leaf buds are used to produce tea.
- Camellia sinensis has been used in Asia for medicinal purposes for thousands of years. In the prior art, it is typically consumed as a beverage and is available as a liquid extract, capsules, tablets and as topical products. It has been reported for use in cancers and heart disease to provide protective effects. Camellia sinensis may also act as a stimulant and can temporarily alleviate the feeling of fatigue and increase an individual's energy level.
- compositions comprising a therapeutically effective amount of Camellia sinensis may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- Camellia sinensis may be present in the composition from about 10 mg to about 500 mg per dose and most preferably from about 100 mg to about 200 mg per dose.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Paullinia cupana (also known as guarana or Brazilian coca).
- Paullinia cupana also known as guarana or Brazilian coca.
- Paullinia cupana is a climbing plant in the maple family, Sapindaceae, native to the Amazon basin and common to Brazil having large leaves and clusters of flowers, best known for the seeds from its fruit which are about the size of a coffee bean.
- Paullinia cupana is a seed that contains more caffeine than coffee beans and is known as a stimulant. The plant thrives in the Amazon rainforest.
- compositions comprising a therapeutically effective amount of Paullinia cupana may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- Paullinia cupana may be present in the composition from about 25 mg to about 1000 mg per dose and most preferably from about 100 mg to about 200 mg per dose.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of folate (folic acid).
- folate may comprise many forms of the vitamin—namely folic acid and its congeners, including tetrahydrofolic acid, methyltetrahydrofolate, methenylterahydrofolate, folinic acid, and folacin.
- folate is considered part of the B vitamins and can be found in forms such as folic acid or vitamin B9.
- folate is found in food and dietary supplements and is considered an essential vitamin since humans are not able to synthesize vitamin B9.
- compositions comprising a therapeutically effective amount of folate may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- folate may be present in the composition from about 25 mcg to about 2000 mcg per dose and most preferably from about 250 mcg to about 400 mcg per dose.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Vitamin B12 (Cobalamin).
- Vitamin B12 is a coenzyme involved in the metabolism of cells of the human body, especially affecting DNA synthesis and regulation, but also fatty acid metabolism and amino acid metabolism.
- Vitamin B12 is a water soluble vitamin that is essential for red blood cell formation, nerve function and DNA production. It is reported to be found in foods such as poultry, meat, fish and dairy products. Deficiency of Vitamin B12 is more common in vegans. Supplementation of Vitamin B12 orally or with IV infusions has been shown to correct this problem and alleviates fatigue.
- compositions comprising a therapeutically effective amount of Vitamin B12 may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- Vitamin B12 may be present in the composition from about 250 mcg to about 2000 mcg per dose and most preferably from about 450 mcg to about 550 mcg per dose.
- the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Fructose.
- Fructose is a simple ketonic monosaccharide found in plants and is a sugar. Persons skilled in the relevant art will also understand that once ingested, the sugar is readily absorbed into the bloodstream during the digestion process, which allows the fructose molecule to enter the blood stream and make its way to the liver where it is metabolized into glucose. Skilled readers will understand that glucose is the body's primary energy source and contributes to improvement of energy levels and alleviating fatigue.
- compositions comprising a therapeutically effective amount of Fructose may preferably serve to increase energy level and/or alleviate fatigue in a patient.
- Fructose may be present in the composition from about 25 mg to about 100 mg per dose and most preferably from about 30 mg to about 70 mg per dose.
- the combination of Cannabis with herbs, vitamins and/or fructose provides advantageous outcomes as the pharmaceutical composition retains the therapeutic benefits of Cannabis on relaxation to enable re-energization while minimizing its potential adverse effects.
- the pharmaceutical composition may preferably, but need not necessarily, be administered in a single or multiple doses prior to bed time to increase energy levels and/or alleviate fatigue.
- a dose is taken once daily or up to four (4) times daily.
- a dosing regimen is continued until the feeling of low energy and/or fatigue has abated.
- the composition of the present invention may be administered once daily to prevent low energy levels and/or fatigue.
- the pharmaceutical composition of the present invention is used as a nutritional supplement to help patients who suffer from decrease energy and/or increased fatigue.
- the pharmaceutical composition of the present invention will preferably increase the energy level of patients and/or minimize the feeling of fatigue.
- the disorders that may be treated by embodiments of the present invention include, but are not limited to, fatigue, lethargy, listless tiredness, malaise, feeling of being run down, worn out, chronic fatigue syndrome, and symptoms caused by treatable medical disorders.
- the pharmaceutical composition of the present invention is preferably formulated in multiple strengths to treat the symptoms associated with the above disorders.
- the pharmaceutical composition of the present invention is preferably formulated to use the minimal therapeutically effective doses of the active ingredients to maximize absorption in the gastrointestinal track (e.g., maximize bioavailability) and minimize side effects.
- the pharmaceutical composition allows for a reduction in the dose of Cannabis required to achieve the same therapeutic effect compared to Cannabis administered to a patient in a traditional dosage form (e.g., smoking or inhalation).
- the pharmaceutical composition is formulated to contain Cannabis comprising a higher dose of THC (delta-9-tetrahydrocannabinol) or at least 2 mg THC per dose or more preferably at least 10 mg THC per dose.
- THC delta-9-tetrahydrocannabinol
- An advantage of such formulations is to prevent the onset of, or contribution to, Cannabis -induced fatigue which has been reported to occur with higher doses of Cannabis.
- the administration of lower doses of Cannabis compared to Cannabis administered in a traditional dosage form, for example, smoking or inhalation
- the herbs, vitamins and fructose disclosed herein is advantageous as it provides a therapeutic effect on improving energy levels and/or alleviating fatigue and a reduction in cravings for further Cannabis that chronic Cannabis users may experience.
- the combination of Cannabis , herbs, vitamins and/or fructose disclosed herein is advantageous as it may provide an unexpected synergistic therapeutic effect on improving energy levels and/or alleviating fatigue.
- the combination of Cannabis , herbs, vitamins and/or fructose disclosed herein is advantageous as it may unexpectedly allow for the use of a lower dose of Cannabis to achieve a similar therapeutic effect when compared to Cannabis administered to a patient in a traditional dosage form (e.g., smoking or inhalation).
- the combination of Cannabis , herbs, vitamins and/or fructose disclosed herein is advantageous as it may allow for the use of a lower dose of Cannabis to reduce the severity and/or number of potential Cannabis -related adverse effects.
- the pharmaceutical composition of the present invention is a formulation comprising Cannabis in addition to various herbs, vitamins and fructose, either used as a medicine prescribed by a physician, a health care practitioner, or an over-the-counter product available in pharmacies, marijuana dispensaries, and mass food stores and will preferably help patients who suffer from sleeping disorders achieve more energy.
- the pharmaceutical composition comprising Cannabis , herbs, vitamins and fructose may be administered once or up to four (4) times daily prior to bedtime during periods of low energy and/or fatigue.
- the pharmaceutical composition of the present invention delivers high concentrations of several herbs and vitamins including Camellia sinensis, Paullinia cupana , Folate, Vitamin B12 (cobalamin), fructose and therapeutically effective concentrations of Cannabis in any form without causing increased side effects.
- the combination of the foregoing herbs, vitamins, fructose and Cannabis in a single formulation to increase energy level and/or alleviate fatigue in a patient is unique and has not been previously described.
- Cannabis administered in predetermined doses in combination with the supplements described herein allows for the body to relax and be re-energized.
- the pharmaceutical composition of the present invention is formulated to provide seemingly paradoxical effects as the predetermined therapeutically effective dose of Cannabis provides patients with an increase in energy level.
- the following example sets out a preferred formulation of the pharmaceutical composition in accordance with the present invention to increase energy level and/or alleviate fatigue in a patient.
- Medicinal Ingredients Quantity Camellia sinensis 156.5 mg Folate 300.0 mcg Fructose 50.0 mg Paullinia cupana 170.4 mg Vitamin B12 500.0 mcg Cannabis (THC) 0.05 g to 2 g of 10% to 50% THC levels
- the formulation is allergen free (e.g., egg products, wheat (gluten) and dairy (lactose)).
- allergen free e.g., egg products, wheat (gluten) and dairy (lactose)
- all compounds in the formulation are preferably gluten free.
- a test formulation comprising a combination of Camellia sinensis (156.5 mg), folate (300.0 mcg), Fructose (50.0 mg), Paullinia cupana (170.4 mg), Vitamin B12 (500.0 mcg), and Cannabis (THC) (0.05 g to 2 g of 10% to 50% THC levels) was prepared in a capsule dosage form to study the effectiveness of the combination on increasing energy level and/or alleviating fatigue in a patient.
- test formulation described above is effective in the increase of energy level and/or reduction of fatigue in a patient.
- the subject experienced greater energy levels and lower anxiety and fatigue. No obvious adverse effects of the test formulation were identified.
- the test formulation may be effective to increase energy levels and/or alleviate fatigue in a patient. Further studies may be needed to qualitatively and/or quantitatively assess improvement in energy levels and reduction in fatigue and to determine the preferred medicinal ingredients (including the preferred quantity of each) to include in the composition as well as the potential adverse effects associated with same.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition containing Cannabis for increasing energy levels and/or alleviating fatigue in a patient. Also provided are a use of the pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient, and methods for increasing energy levels and/or alleviating fatigue. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: Cannabis, an herb, vitamins, and/or fructose.
Description
- The present application is a divisional application of U.S. application Ser. No. 16/734,681, filed Jan. 6, 2020. U.S. application Ser. No. 16/734,681 is a continuation application of U.S. application Ser. No. 16/375,938, filed on Apr. 5, 2019 and issued as U.S. Pat. No. 10,568,920 on Feb. 25, 2020. U.S. application Ser. No. 16/375,938 claims priority to Canadian application number 3000495, filed on Apr. 6, 2018. The entire content of each of the referenced cited above are incorporated herein by reference.
- The present invention relates to pharmaceutical compositions comprising Cannabis and methods for improving energy and/or alleviating fatigue.
- There are an increasing number of patients who describe themselves as feeling fatigue often. Fatigue can be due to physical fatigue associated with excess activity or working out and mental fatigue associated with sleep deprivation, depression, boredom, jet lagged and stress. Mental fatigue does give the subjective feeling of physical fatigue. Fatigue also is commonly caused by many medical conditions such as thyroid disease, heart disease, chronic obstructive pulmonary disease (COPD), anemia, and infectious diseases such as the flu.
- Many individuals do not receive treatment for fatigue as they have not had the cause of the symptoms diagnosed. The prevalence in Ireland is estimated at 25%. (See: Cullen W, Kearney Y, Bury G. Prevalence of fatigue in general practice. Ir J Med Sci, 2002 January-March; 171(1):10-2)
- As common as the disorder is, the number of treatment options is limited. Usually if it is a treatable medical condition such as anemia or a limited disease state such as the flu, patients have the underlying pathology treated with time, rehydration and rest. Similarly, in situations where it is physical fatigue patients can their symptoms improved by rest, rehydration and eating a balanced diet. However, many patients who suffer from mental fatigue have a more challenging time getting relief from the symptoms of fatigue.
- In addition, drugs and alcohol also are known contributors to fatigue. For example, Cannabis is a drug that can cause or contribute to fatigue at higher doses and when formulated with lower levels of THC (tetrahydrocannabinol) or less than about 10 mg of THC.
- What may be needed is a pharmaceutical composition of Cannabis that treats low energy levels and/or fatigue while minimizing associated adverse effects.
- According to an aspect of the present invention, there is disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, comprise alone or in combination, therapeutically effective amounts of Cannabis and/or herbs for use as a medicinal product prescribed by a physician, a health care practitioner or an over-the-counter product available at pharmacies, marijuana dispensaries and/or mass food stores.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Camellia sinesis.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Paullinia cupana (also known as guarana or Brazilian coca).
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Folate.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Vitamin B12.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, additionally comprise therapeutically effective amounts of Fructose.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy level and/or alleviating fatigue in a patient while minimizing side effects. The pharmaceutical composition may preferably, but need not necessarily, comprise therapeutically effective amounts of Cannabis in any of the following form cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC), a naphthoylindole, a phenylacetylindole, a benzoylindole, a cyclohexylphenole, delta-9 tetrahydrocannabinol (THC or dronabinol), delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA), the pharmaceutical agent is CBD, THC or a combination thereof.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient. The pharmaceutical composition may preferably, but need not necessarily, comprise a pharmaceutically acceptable excipient selected from any of the group consisting of: hydroxypropylcellulose, starch, silicon dioxide, gelatin, magnesium stearate, or microcrystalline cellulose.
- According to an aspect of the invention, there is preferably disclosed a pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient. The pharmaceutical composition may preferably, but need not necessarily, comprise the form of a tablet, caplet, capsule, dermal patch, oil drops, powder or a suspension.
- Other advantages, features and characteristics of the present invention, as well as methods of use and applications of the related elements of the pharmaceutical composition and formulation will become more apparent upon consideration of the following detailed description and the appended claims, the latter of which are briefly described hereinbelow.
- The description that follows, and the embodiments described therein, is provided by way of illustration of an example, or examples, of particular embodiments of the principles and aspects of the present invention. These examples are provided for the purposes of explanation, and not of limitation, of those principles and of the invention.
- It should also be appreciated that the present invention can be implemented in numerous ways, including as a use of the pharmaceutical composition or a method for increasing energy levels and/or alleviating fatigue in a patient. In this specification, these implementations, or any other form that the invention may take, may be referred to as uses or methods. In general, the order of the steps of the disclosed methods may be altered within the scope of the invention.
- In this disclosure, a number of terms are used. The following definitions of such terms are provided.
- As used herein, a person skilled in the relevant art may generally understand the term “comprising” to generally mean the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
- As used herein, the skilled reader may generally understand the term “energy” or “energetic” to generally mean to possess, exert, or display the ability to do physical work. It is the ability and strength to do active physical things and a feeling of physical power and life.
- As used herein, the skilled reader may generally understand the term “fatigue” to generally mean a feeling of tiredness which is distinct from weakness and has a gradual onset. Fatigue can have physical or mental causes. Physical fatigue is the transient inability of a muscle to maintain optimal physical performance. Mental fatigue is a transient decrease in maximal cognitive performance resulting from prolonged periods of cognitive activity and can manifest as somnolence, lethargy or directed attention fatigue.
- As used herein, a person skilled in the relevant art may generally understand the term “treatment” to generally refer to an approach for obtaining beneficial or desired results. Beneficial or desired results can include, but are not limited to, prevention or prophylaxis, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- As used herein, a person skilled in the relevant art may generally understand the term “therapeutically effective amount” to be an amount sufficient to effect treatment when administered to a subject in need of treatment. In the case of the embodiments of the present invention, a therapeutically effective amount can include, but is not limited to, an amount for increasing energy levels and/or alleviating fatigue in a patient.
- It will be understood by a person skilled in the relevant art that the compositions of the present invention can be formulated into pharmaceutical compositions for administration in a manner customary for administration of such materials using standard pharmaceutical formulation chemistries and methodologies, all of which are readily available to a person skilled in the relevant art. It will also be understood by a person skilled in the relevant art that such pharmaceutical compositions may include one or more excipients, carriers, stabilizers or other pharmaceutically inactive compounds, such as, but not limited to, wetting or emulsifying agents, pH buffering substances, hydroxypropylcellulose, starch, silicon dioxide, gelatin, magnesium stearate, microcrystalline cellulose and the like. Pharmaceutically acceptable salts can also be included therein. A thorough discussion of pharmaceutically acceptable excipients, vehicles and auxiliary substances is available in Remington's. Pharmaceutical Sciences (Mack Pub. Co. N.J. 1991). Such pharmaceutical compositions can be prepared as oral or transdermal preparations. The therapeutically effective doses may vary according to body weight and the timing and duration of administration will be determined by specific clinical research protocols.
- It will be understood by a person skilled in the relevant art that the term “dose” refers to the measured quantity of an agent, preferably a therapeutic agent, to be taken at one time to have a desired therapeutic effect(s). Preferably, “dose” as used herein means a specified quantity of a pharmaceutical or therapeutic agent provided in one or more administration. It will be further understood that a “dosage unit” or “dosage form” as used herein means a form in which the active agent is provided. It will be understood that any known dosage form may be employed with the present invention. These may include, solid dosage forms, liquid dosage forms, gel dosage forms, etc. The term “effective dose” or “effective dosage” is defined as an amount sufficient to achieve or at least partially achieve the desired effect. The term “therapeutically effective dose” is defined as an amount sufficient to cure or at least partially arrest the disease and/or one or more associated symptoms in a patient already suffering from the disease.
- It will be understood by a person skilled in the relevant art that the term “administering” means providing a therapeutically active agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering.
- It will be understood by a person skilled in the relevant art that a “pharmaceutical agent” or “therapeutic agent” as used herein means a substance that provides a therapeutic effect when administered to a subject. “Pharmaceutical composition” means a mixture of substances suitable for administering to an individual that includes one or more pharmaceutical or therapeutically effective agents. The terms “active pharmaceutical ingredient” shall be understood to refer to a substance in a pharmaceutical composition that provides a desired effect.
- The treatment of low energy levels and/or fatigue in accordance with the present invention and as hereinafter defined for the purposes of this invention is directed to the improvement of energy levels and/or alleviating fatigue—including or in particularly mental fatigue—as defined herein. In a preferred embodiment of the present invention, an agent or agents which can treat low energy levels and/or fatigue is recommended. Since no pharmaceutical composition containing Cannabis is presently capable of treating low energy levels and/or fatigue, a pharmaceutical composition such as is described in the present invention is recommended. Preferred embodiments of the present invention treat low energy levels and/or fatigue.
- Preferably, the pharmaceutical compositions of the present invention may be provided with different active ingredients, different strengths and/or different formulations. Preferably, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Cannabis. A person skilled in the relevant art would understand the term “Cannabis” to refer to a genus of flowering plants in the family Cannabaceae which produce a group of chemicals called cannabinoids that produce physiological effects when administered to a patient. Persons skilled in the art will also readily appreciate that a cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors (e.g., cannabinoid receptor type 1, cannabinoid receptor type 2) in cells that alter neurotransmitter release in the brain. In accordance with one or more preferred embodiments of the invention, the pharmaceutical composition may comprise Cannabis-derived cannabinoids selected from the group consisting of: cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC), a naphthoylindole, a phenylacetylindole, a benzoylindole, a cyclohexylphenole, delta-9 tetrahydrocannabinol (THC or dronabinol), delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA), the pharmaceutical agent is CBD, THC or combinations thereof. In accordance with an aspect of the present invention, compositions comprising a therapeutically effective amount of Cannabis may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, Cannabis may be present in the composition in a particulate form with at least 50% by wt of the particles ranging in size from about 50 micron to about 2000 micron and wherein the particles comprise a cannabinoid, cannabinoid derivative, a terpene or a mixture thereof in a range of 1 to 30 mg of cannabinoid (CBD or THC) and most preferably from about 2.5 mg to about 10 mg per dose.
- The pharmaceutical composition of the present invention may also comprise a therapeutically effective amount of one or more herbs, including but not limited to: Camellia sinensis; Paullinia cupana; and combinations thereof.
- In a preferred embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Camellia sinensis (green tea). Persons skilled in the relevant art would understand the term “Camellia sinensis” to be a species of evergreen shrub or small tree whose leaves and leaf buds are used to produce tea. Persons skilled in the art will appreciate that Camellia sinensis has been used in Asia for medicinal purposes for thousands of years. In the prior art, it is typically consumed as a beverage and is available as a liquid extract, capsules, tablets and as topical products. It has been reported for use in cancers and heart disease to provide protective effects. Camellia sinensis may also act as a stimulant and can temporarily alleviate the feeling of fatigue and increase an individual's energy level. (See: NIH.gov Fact sheet Green Tea) In accordance with the present invention, compositions comprising a therapeutically effective amount of Camellia sinensis may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, Camellia sinensis may be present in the composition from about 10 mg to about 500 mg per dose and most preferably from about 100 mg to about 200 mg per dose.
- In a preferred embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Paullinia cupana (also known as guarana or Brazilian coca). Persons skilled in the relevant art would understand the term “Paullinia cupana” to be a climbing plant in the maple family, Sapindaceae, native to the Amazon basin and common to Brazil having large leaves and clusters of flowers, best known for the seeds from its fruit which are about the size of a coffee bean. Persons skilled in the art will also appreciate that Paullinia cupana is a seed that contains more caffeine than coffee beans and is known as a stimulant. The plant thrives in the Amazon rainforest. It has been reported to have various health benefits such as an ability to ameliorate heat stroke, cardiovascular aid, increase mental focus and acuity and some analgesic qualities. (See: Rafael de Lima Portella, Romulo Pillon Barcelos and Felix Alexandre Antunes Soares, Guarana (Paullinia cupana Kunth) effects on LDL oxidation in elderly people: an in vitro and in vivo study. Lipids Health Dis. 2013; 12:12) In accordance with the present invention, compositions comprising a therapeutically effective amount of Paullinia cupana may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, Paullinia cupana may be present in the composition from about 25 mg to about 1000 mg per dose and most preferably from about 100 mg to about 200 mg per dose.
- In a preferred embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of folate (folic acid). A person skilled in the relevant art would understand that the term “folate” may comprise many forms of the vitamin—namely folic acid and its congeners, including tetrahydrofolic acid, methyltetrahydrofolate, methenylterahydrofolate, folinic acid, and folacin. In the prior art, folate is considered part of the B vitamins and can be found in forms such as folic acid or vitamin B9. Persons skilled in the art will also appreciate that folate is found in food and dietary supplements and is considered an essential vitamin since humans are not able to synthesize vitamin B9. Folate deficiency is known to result in anemia and can cause the feeling of being tired. Folate deficiency occurs in 1 in 10 people in the elderly patient population according to the NHS in the United Kingdom. A paper published in Neurology in 1993 by Dr. Jacobson showed that patients with chronic fatigue also had an increase incidence of Folate deficiency. Supplementing with Folate has been reported to help correct the deficiency and improve fatigue. In accordance with an aspect of the present invention, compositions comprising a therapeutically effective amount of folate may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, folate may be present in the composition from about 25 mcg to about 2000 mcg per dose and most preferably from about 250 mcg to about 400 mcg per dose.
- In a preferred embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Vitamin B12 (Cobalamin). A person skilled in the relevant art would understand that “Vitamin B12” is a coenzyme involved in the metabolism of cells of the human body, especially affecting DNA synthesis and regulation, but also fatty acid metabolism and amino acid metabolism. Persons of skill in the relevant art will also appreciate that Vitamin B12 is a water soluble vitamin that is essential for red blood cell formation, nerve function and DNA production. It is reported to be found in foods such as poultry, meat, fish and dairy products. Deficiency of Vitamin B12 is more common in vegans. Supplementation of Vitamin B12 orally or with IV infusions has been shown to correct this problem and alleviates fatigue. (See: Mayoclinic.org) In accordance with the present invention, compositions comprising a therapeutically effective amount of Vitamin B12 may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, Vitamin B12 may be present in the composition from about 250 mcg to about 2000 mcg per dose and most preferably from about 450 mcg to about 550 mcg per dose.
- In a preferred embodiment, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of Fructose. A person skilled in the relevant art would understand that “Fructose” is a simple ketonic monosaccharide found in plants and is a sugar. Persons skilled in the relevant art will also understand that once ingested, the sugar is readily absorbed into the bloodstream during the digestion process, which allows the fructose molecule to enter the blood stream and make its way to the liver where it is metabolized into glucose. Skilled readers will understand that glucose is the body's primary energy source and contributes to improvement of energy levels and alleviating fatigue. In accordance with an aspect of the present invention, compositions comprising a therapeutically effective amount of Fructose may preferably serve to increase energy level and/or alleviate fatigue in a patient. In accordance with some embodiments of the present invention, Fructose may be present in the composition from about 25 mg to about 100 mg per dose and most preferably from about 30 mg to about 70 mg per dose.
- In a preferred embodiment of the present invention, the combination of Cannabis with herbs, vitamins and/or fructose provides advantageous outcomes as the pharmaceutical composition retains the therapeutic benefits of Cannabis on relaxation to enable re-energization while minimizing its potential adverse effects.
- The pharmaceutical composition may preferably, but need not necessarily, be administered in a single or multiple doses prior to bed time to increase energy levels and/or alleviate fatigue. In preferable, embodiments, a dose is taken once daily or up to four (4) times daily. In a preferred embodiment, a dosing regimen is continued until the feeling of low energy and/or fatigue has abated. In some embodiments, the composition of the present invention may be administered once daily to prevent low energy levels and/or fatigue.
- In a preferred embodiment, the pharmaceutical composition of the present invention is used as a nutritional supplement to help patients who suffer from decrease energy and/or increased fatigue. The pharmaceutical composition of the present invention will preferably increase the energy level of patients and/or minimize the feeling of fatigue. Preferably, the disorders that may be treated by embodiments of the present invention include, but are not limited to, fatigue, lethargy, listless tiredness, malaise, feeling of being run down, worn out, chronic fatigue syndrome, and symptoms caused by treatable medical disorders. The pharmaceutical composition of the present invention is preferably formulated in multiple strengths to treat the symptoms associated with the above disorders. The pharmaceutical composition of the present invention is preferably formulated to use the minimal therapeutically effective doses of the active ingredients to maximize absorption in the gastrointestinal track (e.g., maximize bioavailability) and minimize side effects. In accordance with a preferred embodiment of the present invention, the pharmaceutical composition allows for a reduction in the dose of Cannabis required to achieve the same therapeutic effect compared to Cannabis administered to a patient in a traditional dosage form (e.g., smoking or inhalation).
- In accordance with a preferred embodiment of the present invention, the pharmaceutical composition is formulated to contain Cannabis comprising a higher dose of THC (delta-9-tetrahydrocannabinol) or at least 2 mg THC per dose or more preferably at least 10 mg THC per dose. An advantage of such formulations is to prevent the onset of, or contribution to, Cannabis-induced fatigue which has been reported to occur with higher doses of Cannabis.
- In accordance with a preferred embodiment of the present invention, the administration of lower doses of Cannabis (compared to Cannabis administered in a traditional dosage form, for example, smoking or inhalation) combined with the herbs, vitamins and fructose disclosed herein is advantageous as it provides a therapeutic effect on improving energy levels and/or alleviating fatigue and a reduction in cravings for further Cannabis that chronic Cannabis users may experience.
- In accordance with a preferred embodiment of the present invention, the combination of Cannabis, herbs, vitamins and/or fructose disclosed herein is advantageous as it may provide an unexpected synergistic therapeutic effect on improving energy levels and/or alleviating fatigue.
- In accordance with a preferred embodiment of the present invention, the combination of Cannabis, herbs, vitamins and/or fructose disclosed herein is advantageous as it may unexpectedly allow for the use of a lower dose of Cannabis to achieve a similar therapeutic effect when compared to Cannabis administered to a patient in a traditional dosage form (e.g., smoking or inhalation).
- In accordance with a preferred embodiment of the present invention, the combination of Cannabis, herbs, vitamins and/or fructose disclosed herein is advantageous as it may allow for the use of a lower dose of Cannabis to reduce the severity and/or number of potential Cannabis-related adverse effects.
- The pharmaceutical composition of the present invention is a formulation comprising Cannabis in addition to various herbs, vitamins and fructose, either used as a medicine prescribed by a physician, a health care practitioner, or an over-the-counter product available in pharmacies, marijuana dispensaries, and mass food stores and will preferably help patients who suffer from sleeping disorders achieve more energy.
- In accordance with a preferred embodiment of the present invention, the pharmaceutical composition comprising Cannabis, herbs, vitamins and fructose may be administered once or up to four (4) times daily prior to bedtime during periods of low energy and/or fatigue. The pharmaceutical composition of the present invention delivers high concentrations of several herbs and vitamins including Camellia sinensis, Paullinia cupana, Folate, Vitamin B12 (cobalamin), fructose and therapeutically effective concentrations of Cannabis in any form without causing increased side effects. The combination of the foregoing herbs, vitamins, fructose and Cannabis in a single formulation to increase energy level and/or alleviate fatigue in a patient is unique and has not been previously described.
- Persons skilled in the relevant art may find it counterintuitive to find that Cannabis may improve energy levels when it has been reported to cause sleepiness. In accordance with preferred embodiments of the present invention, however, Cannabis administered in predetermined doses in combination with the supplements described herein allows for the body to relax and be re-energized. The pharmaceutical composition of the present invention is formulated to provide seemingly paradoxical effects as the predetermined therapeutically effective dose of Cannabis provides patients with an increase in energy level.
- The following example sets out a preferred formulation of the pharmaceutical composition in accordance with the present invention to increase energy level and/or alleviate fatigue in a patient.
-
Medicinal Ingredients Quantity Camellia sinensis 156.5 mg Folate 300.0 mcg Fructose 50.0 mg Paullinia cupana 170.4 mg Vitamin B12 500.0 mcg Cannabis (THC) 0.05 g to 2 g of 10% to 50% THC levels - In preferred embodiments of the invention, the formulation is allergen free (e.g., egg products, wheat (gluten) and dairy (lactose)). In addition, all compounds in the formulation are preferably gluten free.
- Background:
- A test formulation comprising a combination of Camellia sinensis (156.5 mg), folate (300.0 mcg), Fructose (50.0 mg), Paullinia cupana (170.4 mg), Vitamin B12 (500.0 mcg), and Cannabis (THC) (0.05 g to 2 g of 10% to 50% THC levels) was prepared in a capsule dosage form to study the effectiveness of the combination on increasing energy level and/or alleviating fatigue in a patient.
- Objective:
- To assess whether the test formulation described above is effective in the increase of energy level and/or reduction of fatigue in a patient.
- Methods:
- A 30 year old male experiences anxiety and suffers from decreased energy. The subject was administered the capsule formulation twice daily for two weeks and then qualitatively assessed for energy level and fatigue.
- Results:
- The subject experienced greater energy levels and lower anxiety and fatigue. No obvious adverse effects of the test formulation were identified.
- Conclusions:
- The test formulation may be effective to increase energy levels and/or alleviate fatigue in a patient. Further studies may be needed to qualitatively and/or quantitatively assess improvement in energy levels and reduction in fatigue and to determine the preferred medicinal ingredients (including the preferred quantity of each) to include in the composition as well as the potential adverse effects associated with same.
- The above description is meant to be exemplary only, and one skilled in the art will recognize that changes may be made to the embodiments described without departing from the scope of the invention disclosed. Modifications which fall within the scope of the scope of the present invention will be apparent to those skilled in the art, in light of a review of this disclosure, and such modifications are intended to fall within the appended claims.
- This concludes the description of presently preferred embodiments of the invention. The foregoing description has been presented for the purpose of illustration and is not intended to be exhaustive or to limit the invention to the precise form disclosed. Other modification, variations and alterations are possible in light of the above teaching and will be apparent to those skilled in the art, and may be used in the design and manufacture of other embodiments according to the present invention without departing from the spirit and scope of the invention. It is intended the scope of the invention be limited not by this description but only by the claims forming a part hereof.
Claims (11)
1. A tablet, caplet, capsule or dermal patch consisting of a Cannabis extract, a Paullinia cupana extract: Vitamin B9, Vitamin B 12 and fructose.
2. The tablet, caplet, capsule or dermal patch of claim 1 wherein the tablet, caplet, capsule or dermal patch consists of from about 25 mg to about 1000 mg of the Paullinia cupana extract per dose.
3. The tablet, caplet, capsule or dermal patch of claim 2 wherein the tablet, caplet, capsule or dermal patch consists of from about 100 mg to about 200 mg of the Paullinia cupana extract per dose.
4. The tablet, caplet, capsule or dermal patch of claim 1 wherein the tablet, caplet, capsule or dermal patch consists of from about 1 mg to about 30 mg of the Cannabis extract per dose.
5. The tablet, caplet, capsule or dermal patch of claim 4 wherein the tablet, caplet, capsule or dermal patch consists of from about 2.5 mg to about 10 mg of the Cannabis extract per dose.
6. The tablet, caplet, capsule or dermal patch of claim 1 wherein the tablet, caplet, capsule or dermal patch consists of from about 25 mcg to about 2000 mcg of Vitamin B9 per dose.
7. The tablet, caplet, capsule or dermal patch of claim 6 wherein the tablet, caplet, capsule or dermal patch consists of from about 250 mcg to about 400 mcg of Vitamin B9 per dose.
8. The tablet, caplet, capsule or dermal patch of claim 1 wherein the tablet, caplet, capsule or dermal patch consists of from about 250 mcg to about 2000 mcg of Vitamin B 12 per dose.
9. The tablet, caplet, capsule or dermal patch of claim 8 wherein the tablet, caplet, capsule or dermal patch consists of from about 450 mcg to about 550 mcg of Vitamin B 12 per dose.
10. The tablet, caplet, capsule or dermal patch of claim 9 wherein the tablet, caplet, capsule or dermal patch consists of from about 25 mg to about 100 mg of the fructose per dose.
11. The tablet, caplet, capsule or dermal patch of claim 10 wherein the tablet, caplet, capsule or dermal patch consists of from about 30 mg to about 70 mg of the fructose per dose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/717,203 US20220233621A1 (en) | 2018-04-06 | 2022-04-11 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3000495A CA3000495A1 (en) | 2018-04-06 | 2018-04-06 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
CA3000495 | 2018-04-06 | ||
US16/375,938 US10568920B2 (en) | 2018-04-06 | 2019-04-05 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
US16/734,681 US11311587B2 (en) | 2018-04-06 | 2020-01-06 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
US17/717,203 US20220233621A1 (en) | 2018-04-06 | 2022-04-11 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/734,681 Division US11311587B2 (en) | 2018-04-06 | 2020-01-06 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220233621A1 true US20220233621A1 (en) | 2022-07-28 |
Family
ID=68097709
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/375,938 Expired - Fee Related US10568920B2 (en) | 2018-04-06 | 2019-04-05 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
US16/734,681 Active US11311587B2 (en) | 2018-04-06 | 2020-01-06 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
US17/717,203 Abandoned US20220233621A1 (en) | 2018-04-06 | 2022-04-11 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/375,938 Expired - Fee Related US10568920B2 (en) | 2018-04-06 | 2019-04-05 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
US16/734,681 Active US11311587B2 (en) | 2018-04-06 | 2020-01-06 | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue |
Country Status (2)
Country | Link |
---|---|
US (3) | US10568920B2 (en) |
CA (1) | CA3000495A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022200608A1 (en) * | 2021-03-25 | 2022-09-29 | Société des Produits Nestlé S.A. | Substituted resorcylic acid compounds in the management of ageing and related disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071053B2 (en) * | 2014-01-31 | 2018-09-11 | Pocket Tea, Llc | Tea composition for oral administration |
RU2018102137A (en) * | 2015-06-19 | 2019-07-19 | Глобал Хелс Солюшенз, Ллк. | DELIVERY SYSTEMS BASED ON VAZELINE AND FOR ACTIVE INGREDIENTS |
-
2018
- 2018-04-06 CA CA3000495A patent/CA3000495A1/en active Pending
-
2019
- 2019-04-05 US US16/375,938 patent/US10568920B2/en not_active Expired - Fee Related
-
2020
- 2020-01-06 US US16/734,681 patent/US11311587B2/en active Active
-
2022
- 2022-04-11 US US17/717,203 patent/US20220233621A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10568920B2 (en) | 2020-02-25 |
US11311587B2 (en) | 2022-04-26 |
US20190307826A1 (en) | 2019-10-10 |
CA3000495A1 (en) | 2019-10-06 |
US20200254040A1 (en) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7745487B2 (en) | Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions | |
US7115285B2 (en) | Composition and method for appetite and craving suppression and mood enhancement | |
KR100680121B1 (en) | Formulation containing lyso-phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
US20190307720A1 (en) | Pharmaceutical Compositions Containing Cannabis, Uses Thereof and Methods for Alleviating Stress and/or Anxiety | |
ZA200604097B (en) | Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences | |
US20070299040A1 (en) | Composition for Preventing a Cold | |
AU2014282942B2 (en) | Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
WO2018112475A1 (en) | Energy compositions and methods | |
US20220233621A1 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue | |
US10561694B2 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality | |
JP2018506524A (en) | Composition for prevention, amelioration or treatment of burnout syndrome | |
US20160129064A1 (en) | Method for treating metabolic syndrome and diabetes using quercetin and bauhinia forficata extract | |
US10251924B2 (en) | Compositions containing myristica fragrans | |
CN106692667A (en) | Composition with effects of reducing blood pressure, blood fat and blood glucose and use of composition | |
US8975236B2 (en) | Dietary supplement composition of citrus derivatives | |
JP6698034B2 (en) | Oral composition for improving systemic symptoms such as chills | |
CN111093670A (en) | Tertiary-based supplements and methods of use thereof in synergistic combinations with caffeine | |
US20230139125A1 (en) | Dietary supplement for improving brain performance | |
CN112999218A (en) | Composition with effects of calming and helping sleep and application | |
WO2021247447A1 (en) | Antiviral compositions | |
DONATO | PURPORTED USES Cancer prevention Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |